According to a recent LinkedIn post from Circulate, leaders from government, science, and healthcare convened at the EPA to focus on microplastics as an emerging environmental health issue. The post points to the launch of STOMP (Systematic Targeting of Microplastics), described as a $144 million federal initiative to measure microplastics in the human body and develop scalable removal strategies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that the five-year initiative aims to build gold-standard measurement frameworks for microplastics exposure and clinically meaningful thresholds. It notes that Dr. Matt Campen, a scientific advisor to Circulate Health, is participating on a national panel, suggesting some scientific visibility for the company within this policy and research effort.
Circulate’s LinkedIn post highlights that the company’s research and clinical work with Therapeutic Plasma Exchange (TPE) is thematically aligned with the broader push to understand and potentially reduce circulating environmental burdens. For investors, this alignment may signal that Circulate is positioning itself in a nascent but potentially high-impact segment of environmental health and longevity-focused care.
If STOMP succeeds in defining clinical relevance and standardized measurement, the post implies that demand could grow for diagnostic and interventional solutions targeting microplastics and related contaminants. Circulate’s involvement through advisors and leadership presence at the event may enhance its credibility and network in this field, which could support future partnerships, funding opportunities, or clinical adoption pathways over the medium term.